DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening for Drug Repositioning and Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) from APExBIO contains 2,320 regulatory-approved bioactive compounds, facilitating high-throughput screening (HTS) and high-content screening (HCS) applications in drug discovery (APExBIO product page). Compounds are pre-dissolved at 10 mM in DMSO and validated for stability up to 24 months at -80°C. The library supports drug repositioning and pharmacological target identification across diverse disease models (Yang et al., 2023). Mechanisms covered include receptor agonists/antagonists, enzyme inhibitors, ion channel modulators, and signal pathway regulators. The collection includes clinically-relevant agents such as doxorubicin, metformin, and atorvastatin, providing a robust foundation for translational research.

Biological Rationale

Drug repositioning leverages existing clinically approved molecules to identify new therapeutic indications, reducing time and cost compared to de novo drug development (Yang et al., 2023). High-throughput and high-content screening of FDA-approved bioactive compound libraries such as DiscoveryProbe™ accelerate identification of candidates with known safety profiles. The broad mechanistic diversity of the 2,320 compounds enables interrogation of receptor, enzyme, transporter, and signaling pathway targets relevant to cancer, neurodegenerative, and metabolic diseases. This approach also facilitates rapid exploration of resistance mechanisms and off-target effects common in clinical settings. Compared to custom compound collections, regulatory-validated libraries ensure translational relevance and reproducibility (Related article; this article details recent mechanistic expansions and new benchmarks beyond its scope).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library encompasses compounds with well-defined and characterized mechanisms, including:

• Receptor Agonists/Antagonists: Modulators of GPCRs, ion channels, and hormone receptors.
• Enzyme Inhibitors: Targeting kinases (e.g., FLT3), oxidoreductases, and proteases relevant to oncology and metabolic disorders.
• Ion Channel Modulators: Regulating calcium, potassium, and sodium channels, critical for neurodegenerative disease research.
• Signal Pathway Regulators: Affecting AMPK, LKB1, and other signaling cascades involved in cell death and proliferation (Yang et al., 2023).

Representative compounds such as doxorubicin (topoisomerase II inhibitor), metformin (AMPK activator), and atorvastatin (HMG-CoA reductase inhibitor) exemplify the library’s coverage of major pharmacological classes. This diversity supports analyses of drug synergy, resistance, and mechanism-of-action mapping in HTS/HCS workflows (Related article; this review focuses on workflow acceleration, while the current article details evidence and benchmarking data).

Evidence & Benchmarks

• Screening of 1,972 FDA-approved small molecule compounds enabled identification of Motolimod, a TLR8 agonist, as an inducer of caspase-3-dependent inflammatory cell death in acute myeloid leukemia (AML) models (Yang et al., 2023).
• Motolimod demonstrated selective anti-AML activity in vivo with minimal impact on normal lymphocytes, supporting the value of FDA-approved libraries for target selectivity studies (Yang et al., 2023).
• Drug repositioning screens with regulatory-approved libraries have enabled rapid identification of FLT3, BCL2, and IDH1/2 inhibitors that translate into clinical candidates for hematological malignancies (Yang et al., 2023).
• Pre-dissolved 10 mM DMSO solutions display stability for 12 months at -20°C and up to 24 months at -80°C, ensuring reproducibility in long-term screening campaigns (Product page).
• HTS/HCS using the DiscoveryProbe™ FDA-approved Drug Library has accelerated identification of chemosensitizers and novel therapeutic candidates in oncology and neurodegeneration (Related article; this article updates with expanded disease models and mechanistic focus).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library has demonstrated utility in:

• Drug Repositioning Screening: Identifying novel uses for existing drugs in oncology, neurodegeneration, and rare diseases.
• Pharmacological Target Identification: Mapping compound-target relationships to discover new therapeutic mechanisms.
• Signal Pathway Regulation: Dissecting complex signaling networks using compounds with known modes of action.
• High-Content and High-Throughput Screening: Enabling rapid, scalable screening in 96-well, deep-well, and 2D barcoded formats.

Common Pitfalls or Misconceptions

• Not all compounds are suitable for in vivo use: While all are clinically approved, formulations and dosing for animal models may require optimization.
• Library does not include investigational or preclinical compounds: Only agents with regulatory or pharmacopeial approval are included.
• Off-label activities may not always translate to efficacy: Positive screening hits require further validation in disease-relevant models.
• Compound stability is temperature-dependent: Storage above -20°C reduces shelf-life and may impact screening outcomes.
• HTS/HCS does not replace mechanistic validation: Follow-up studies are required to confirm target engagement and clinical relevance.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is provided as pre-dissolved 10 mM solutions in DMSO, compatible with standard liquid handling systems. Available formats include 96-well microplates, deep-well plates, and 2D barcoded screw-top storage tubes (L1021 kit). Compounds are stable for 12 months at -20°C and up to 24 months at -80°C; routine QC is recommended for extended storage. Shipping is performed on blue ice for evaluation samples, with room temperature or blue ice options for bulk orders. The library integrates into workflows for signal pathway analysis, disease model screening, and mechanistic studies, supporting robust experimental reproducibility (Related article; this article focuses on translational imperatives, whereas the current article clarifies real-world integration details).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library from APExBIO provides a comprehensive, stable, and translationally relevant resource for drug repositioning, high-throughput screening, and pharmacological target identification. Its regulatory-approved composition ensures high clinical relevance and reproducibility, while diverse mechanisms of action enable broad biomedical applications. Ongoing integration with advanced HTS/HCS platforms and disease modeling promises continued acceleration of therapeutic discovery and translational research. Researchers are encouraged to leverage this resource for robust, mechanistically informed screening and validation workflows (Product details).